Gore Viabahn Endoprosthesis With Larger Diameter and Lower Profile Launched in EMEA Markets

September 22, 2021—Gore & Associates, Inc. announced the launch in the Europe, Middle East, and Africa (EMEA) markets of the lower profile, large-diameter Gore Viabahn endoprosthesis with Propaten bioactive surface. The device enhancements build on the company’s existing stent graft device for treating complex vascular disease.

According to Gore, the design of the Viabahn device reduces the delivery profile for larger 9- to 13-mm diameter stent grafts by up to 3 F, enabling delivery through smaller sheaths. Smaller introducer sheaths have been shown to result in a lower risk of vascular access complications in select patient populations, noted the company.

Gore further stated that new radiopaque markers, now also on the larger diameter device configurations, enhance visualization under fluoroscopy, facilitating positioning and device delivery, as well as precise and predictable placement.

“In addition to the radiopaque markers that facilitate positioning and deployment, the new lower profile enables use of a smaller sheath, potentially reducing the risk of damage at the access site,” commented Manuel Alonso, MD, in the Gore press release. Dr. Alonso, who is a vascular surgeon in Oviedo, Spain, continued, “Combined with the trackability and flexibility this new lower profile offering will become very instrumental for treating complex patients across disease states in my practice.”

Launched in Europe in 1996, the Viabahn device is used in various clinical indications including superficial femoral artery (SFA) lesions, iliac lesions, in-stent restenosis of SFA lesions, and arteriovenous access circuit lesions, advised Gore & Associates.